<div id="readability-page-1">04:16 AM EST, 12/15/2025 (MT Newswires) -- Johnson &amp; Johnson ( JNJ ) said late Friday that the US Food and Drug Administration has approved the supplemental new drug application for Akeega plus prednisone for the treatment of patients with a certain indication of metastatic castration-sensitive prostate cancer.The approval was based on positive results from a phase 3 clinical study in which the drug combination significantly reduced the risk of radiographic progression or death by 54% compared with a placebo, the company said. It also prolonged the time to symptomatic progression by 59%, the company said.The safety profile of the combination was consistent with other FDA-approved therapies, the company said.Prostate cancer patients with the indication, called a BRCA mutation, often have more aggressive forms of the disease, the company said. MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.</div>

强生

强生宣布其前列腺癌疗法 Akeega 联合泼尼松获得 FDA 批准，针对带有 BRCA 突变的转移性去势敏感性前列腺癌。该批准基于一项三期研究，显示放射学进展或死亡风险降低 54%，症状进展延迟 59%。其安全性特征与其他 FDA 批准的疗法一致

强生的前列腺癌治疗申请已获美国 FDA 批准